Studienliste - Universitätsklinik für Medizinische Onkologie und Universitätsklinik für Radio-Onkologie - Inselspital Kontakt

58 Aktive Studien der Universitätsklinik für Medizinische Onkologie und Universitätsklinik für Radio-Onkologie

FACHGEBIETE

andere

Ordner-Nr. 181/11

  • The radiation metabolic signature of patients undergoing radiotherapy. A Pilot Study
 Studienleiter:Fr. Dr. Kristina Lössl
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 17.01.2014

 

Ordner-Nr. 092/14

  • SAKK 96/12: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Olivia Aerni
 Back-up:Frau Farzaneh Borner


Status: aktiv seit 17.11.2014

 

Ordner-Nr.

  • SENS: A structured early palliative care intervention for patients with advanced cancer – a randomized controlled trial with a nested qualitative study SENSTrial)

    Kurzprotokoll
 Studienleiter:Prof. Dr. med. Steffen Eychmüller
 Co-Investigator:Frau Monica Fliedner
 Study-Nurse:Frau Renata Bünter


Status: aktiv seit 01.12.2013

 

Ordner-Nr.

  • PALL-DEC: Clinical decision-making in palliative situations: The role and prerequisites of patients’ mental representation.
 Studienleiter:Prof. Dr. Jürg Bernhard
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio


Status: aktiv seit 20.10.2014

 

Ordner-Nr. 2016-00520

  • Genetic characterization and enumeration of single, circulating tumour cells isolated from blood of renal cell carcinoma patients.
 Studienleiter:Dr. med. Julian Schardt
Hinweis: Studie wird nicht durch die KFE der UKMO betreut.


Status: aktiv seit 16.06.2016

 

Ordner-Nr. 2016-00008

  • DOSIS Studie: Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases (DOSIS) versus Conventional Radiation Therapy: a Phase II Randomized Controlled Trial.
 Studienleiter:Fr. Dr. med. Evelyn Herrmann


Status: aktiv seit 16.08.2017

 

Ordner-Nr. 2016-00602

  • PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
 Studienleiter:Prof. Dr. Carlo Largiader
 Co-Investigator:Prof. Dr. Daniel Aebersold
 Study-Nurse:Dr. med. Marc Wehrli


Status: aktiv seit 07.09.2017

 

Ordner-Nr. 2016-01487

  • EORTC_31102_TIGER_1407-GUCG: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 21.12.2017

 
zurück nach oben

Blase

Ordner-Nr. 2017-01240

  • NITIMIB-Trial: Neoadjuvant Immunotherapy with Durvalumab in Combination with Tremelimumab in Patients with Muscle-invasive Bladder cancer ineligible for Cisplatin-based Chemotherapy. A Single center, Open-label, Phase II trial."
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Silvia Andrist
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.06.2018

 
zurück nach oben

Hirn

Ordner-Nr.

  • RESURGE: Randomized controlled comperative phase II trial on surgery for glioblastoma recurrence

    Kurzprotokoll
 Studienleiter:PD Dr. med. Philippe Schucht
 Co-Investigator:Prof. Dr. Adrian Ochsenbein
 Study-Nurse:Frau Karin Lussi
Hinweis: Diese Studie wird durch die Neurochirurgie durchgeführt.


Status: aktiv seit 18.05.2015

 

Ordner-Nr.

  • IOSI-RTO-001: Stereotactic Radiosurgery or Hypofractionated Image-Guided Radiotherapy to the surgical cavity after resection of brain metastases: a multicenter, single arm, open-label, phase II trial
 Studienleiter:Fr. Dr. med. Evelyn Herrmann
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 04.09.2018

 

Ordner-Nr. 2016-00707

  • SAKK 67/15 BASILEA (CDI-CS-003): An open-label Phase 1/2a study of BALI 01553 administered as intravenous 48-hour infusions in adult patients with advanced solid tumors or recurrent glioblastoma.
 Studienleiter:Fr. Dr. med. Nurgül Usluoglu
 Co-Investigator:Dr. med. Simon Häfliger
 Study-Nurse:Frau Sandrina Hohl


Status: aktiv seit 19.11.2018

 
zurück nach oben

Hoden

  • zur Zeit keine aktive Studie
zurück nach oben

Kolorektal

Ordner-Nr. 2017-0015

  • Amgen 20140299: A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Co-Investigator:Dr. med. Martin Berger
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.02.2018

 

Ordner-Nr. 2016-00550

  • SAKK 41/13 - Aspirin: Adjuvant aspirin Treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, palcebo-controlled, phase III trial.
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Nicole Corballis


Status: aktiv seit 08.01.2018

 

Ordner-Nr. 2016-01778

  • SAKK 41/16 (RECAP): Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal cancer. A multicenter phase Ib trial (RECAP).
 Studienleiter:Dr. med. Martin Berger
 Study-Nurse:Frau Antje Kramer
 Back-up:Frau Nicole Corballis


Status: aktiv seit 02.10.2018

 
zurück nach oben

Kopf/Hals

Ordner-Nr. 2016-00733

  • UP-FRONT NECK Trial: Definitive (chemo)-radiotherapy with or without up-front neck dissection for regionally advanced Head and Neck Squamous Cell Carcinoma - A phase III multi-center prospective randomized controlled trial with two additional observational cohort”
 Studienleiter:Dr. med. Olgun Elicin
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.12.2016

 
zurück nach oben

Leber/Gallengang

  • zur Zeit keine aktive Studie
zurück nach oben

Leukämien

Ordner-Nr. 256/14

  • HOVON 103 AML / SAKK 30/10 Selinexor: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged  66 years .
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich
 Back-up:Frau Christine Tromp
Hinweis: The required number of 100 (eligible) patients for the interim analysis of the HOVON 103 AML Selinexor study has almost been reached. The interim analysis regarding efficacy will be performed when 50 patients will be evaluable for CR in each arm (ie, at N=50/50). Depending on the outcome of the interim analysis it may be decided that the study should be stopped because of inefficacy. To avoid possible unnecessary treatment of patients with study drug it has been decided to put the inclusion of patients on hold when 100 evaluable patients (50 patients in each arm) have been randomized. With the current inclusion rate we expect that the study will be put on hold for inclusion of new patients within 6 weeks. Mitteilung der SAKK vom 8.11.2018


Status: aktiv seit 10.08.2017

 

Ordner-Nr. 346/15 (PB_2016-0054

  • GRAALL-2014 + GRAAPH-2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years). Comprising 3 sub-studies according to lineage GRAALL-2014/B Ph-negative B-lineage ALL GRAALL-2014/T T-ALL GRAAPH-2014 Ph+ ALL
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 22.02.2017

 

Ordner-Nr. 2016-01125

  • ARGX-110: A Phase I/II, open-label, dose-escalating study with a proof of concept cohort to evaluate the safety, tolerability,and efficacy of ARGX-110 in combination with azacytidine in subjects with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS)
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Prof. Dr. Adrian Ochsenbein
 Study-Nurse:Frau Karin Pagalies
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 26.02.2018

 

Ordner-Nr.

  • CLL 13: EINE PROSPEKTIVE, UNVERBLINDETE, MULTIZENTRISCHE PHASE-III-STUDIE ZUM VERGLEICH VON VIER KOMBINATIONSTHERAPIEN BEI PATIENTEN MIT UNBEHANDELTER CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL) OHNE DEL(17P) ODER TP53 MUTATION: STANDARDCHEMOIMMUNTHERAPIE (FCR/BR), RITUXIMAB UND VENETOCLAX (RVE), OBINUTUZUMAB (GA101) UND VENETOCLAX (GVE) SOWIE OBINUTUZUMAB, IBRUTINIB UND VENETOCLAX (GIVE)
 Studienleiter:Dr. med. Andres Martin
 Co-Investigator:Dr. med. Urban Novak
 Study-Nurse:Frau Karin Pagalies
 Back-up:Frau Bettina Cliffe


Status: aktiv seit 18.09.2017

 

Ordner-Nr. 2018-00606

  • Novartis CPKC412E2301: A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Christine Tromp
 Back-up:Frau Bettina Cliffe


Status: aktiv seit 13.11.2018

 
zurück nach oben

Lunge (NSCLC)

Ordner-Nr. 249/15 (PB_2016-0030

  • MK-3475-091_EORTC 1416-LCG (PEARLS): A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS).

    Kurzprotokoll
 Studienleiter:Fr. Dr. med. Amina Scherz
 Co-Investigator:Prof. Dr. Adrian Ochsenbein
 Study-Nurse:Frau Sandrina Hohl
 Back-up:Frau Olivia Aerni


Status: aktiv seit 28.07.2016

 

Ordner-Nr. 2015-00042 (376/15)

  • SAKK 16/14: Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
 Studienleiter:Prof. Dr. Adrian Ochsenbein
 Co-Investigator:Fr. Dr. med. Amina Scherz
 Study-Nurse:Frau Farzaneh Borner
 Back-up:Frau Nicole Corballis


Status: aktiv seit 05.07.2016

 
zurück nach oben

Lunge (SCLC)

  • zur Zeit keine aktive Studie
zurück nach oben

Lymphome: Diverse

Ordner-Nr. 176/13

  • IELSG 37: Assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens, newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL). Phase III

    Kurzprotokoll
 Studienleiter:Fr. Dr. Codruta Ionescu
 Study-Nurse:Frau Brigitte Dorn
 Back-up:Herr Timo Nannen


Status: aktiv seit 23.01.2014

 

Ordner-Nr. 055/15

  • SAKK 36/13: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase II trial

    Kurzprotokoll
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Bettina Cliffe


Status: aktiv seit 28.11.2016

 

Ordner-Nr. 194/15

  • SAKK 35/14: Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial

    Externer Link
    Kurzprotokoll
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Bettina Cliffe


Status: aktiv seit 09.11.2015

 

Ordner-Nr. 2016-01351

  • BAL-trial: Brentuximab Vedotin and BeEAM high-dose chemotherapy (B-BeEAM) with autologous stem cell transplantation for CD30+ lymphomas, a phase I/II study (the BAL-trial).
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Dr. med. Urban Novak
 Study-Nurse:Frau Sandrina Hohl
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 03.09.2018

 

Ordner-Nr. 2016-01521

  • SAKK 35/15: A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Sandrina Hohl
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 14.05.2018

 

Ordner-Nr. 2016-01917

  • 4SC-201-6-2015: A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Anke Klingenberg-Rettich
 Back-up:Frau Christine Tromp


Status: aktiv seit 01.02.2018

 

Ordner-Nr. 3380

  • Amgen Protocol Number (Capilano) 20150291: A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation
 Studienleiter:Frau Dr. med. Barbara Jeker
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Karin Pagalies
 Back-up:Frau Yaël Balderer


Status: aktiv seit 08.03.2018

 

Ordner-Nr. 3473

  • HOVON 127 / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich


Status: aktiv seit 07.05.2018

 

Ordner-Nr. 2017-01223

  • PAMAL trial: Pedometer-based activity monitoring after autologous transplantation in lymphoma and myeloma patients.
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Irene Briner


Status: aktiv seit 20.11.2017

 

Ordner-Nr. 3549

  • TRIANGLE (SAKK): Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in generalized mantle cell Lymphoma - a randomized european mcl network trial.
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Christine Tromp
 Back-up:Frau Yaël Balderer


Status: aktiv seit 13.03.2018

 

Ordner-Nr. 2018-00162

  • Amgen 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Doris Jäggi-Meinken


Status: aktiv seit 11.07.2018

 

Ordner-Nr. 2018-00828

  • Symptom prevalence and health related quality of life in patients with lymphoma undergoing high-dosage chemotherapy and autologous stem cell transplantation – a longitudinal observation study


Status: aktiv seit 06.07.2018

 
zurück nach oben

Lymphome: Hodgkin

Ordner-Nr. 2016-02186

  • HD 21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Bettina Cliffe
 Back-up:Frau Karin Pagalies


Status: aktiv seit 07.07.2017

 
zurück nach oben

Lymphome: Multiples Myelom

Ordner-Nr. 2016-00442

  • BEB-2 Trial: A randomized phase II trial comparing Bendamustine and Melphalan with Melphalan alone as conditioning regimen for autologous stem cell transplantation (ASCT) in myeloma patients (BEB-2 trial).
 Studienleiter:Prof. Dr. Thomas Pabst
 Co-Investigator:Fr. Dr. med. Sarah Farag
 Study-Nurse:Frau Anke Klingenberg-Rettich


Status: aktiv seit 20.07.2017

 

Ordner-Nr. 2018-00615

  • MOCCCA-trial: A randomized phase II trial comparing stem cell mobilization with hemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients.
 Studienleiter:Frau Dr. med. Barbara Jeker
 Co-Investigator:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Monika-Krista Zackel
 Back-up:Frau Anke Klingenberg-Rettich


Status: aktiv seit 20.09.2018

 

Ordner-Nr. 2018-00820

  • SAKK 39/16 OptiPOM : Alternate day dosing of Pomalidomide in patients with refractory Multiple Myeloma. A multicenter, single arm, open label phase II trial
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Anke Klingenberg-Rettich


Status: aktiv seit 19.11.2018

 

Ordner-Nr. 2017-01223

  • PAMAL Trial: Pedometer-based activity monitoring after autologous transplantation in lymphoma and myeloma patients.
 Studienleiter:Prof. Dr. Thomas Pabst
 Study-Nurse:Frau Irene Briner


Status: aktiv seit 21.11.2017

 
zurück nach oben

Magen

  • zur Zeit keine aktive Studie
zurück nach oben

Mamma

Ordner-Nr. 018/2015

  • IBCSG 48-14 POSITIVE: A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Olivia Aerni
 Back-up:Frau Farzaneh Borner


Status: aktiv seit 30.05.2016

 
zurück nach oben
"Prevention (Postmenopausal)"
  • zur Zeit keine aktive Studie
zurück nach oben
"Early"

Ordner-Nr. 271/14

  • IBCSG 50-14 / BIG 14-02 OLYMPIA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

    Kurzprotokoll
 Studienleiter:Dr. med. Urban Novak
 Co-Investigator:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Farzaneh Borner
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.09.2017

 
zurück nach oben
"Lokalrezidiv"
  • zur Zeit keine aktive Studie
zurück nach oben
"Advanced"

Ordner-Nr. 2016-01006

  • SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer - A multicenter single arm phase II Trial.
 Studienleiter:Dr. med. Urban Novak
 Study-Nurse:Frau Olivia Aerni


Status: aktiv seit 15.04.2017

 

Ordner-Nr. 2017-0015

  • Amgen 20140299: A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Co-Investigator:Dr. med. Martin Berger
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 01.02.2018

 
zurück nach oben
"Male"
  • zur Zeit keine aktive Studie
zurück nach oben

Melanom

  • zur Zeit keine aktive Studie
zurück nach oben

Mesotheliom

  • zur Zeit keine aktive Studie
zurück nach oben

Neuroendokrine Tumoren

Ordner-Nr. 2017-00466

  • COMPETE: A prospective, randomised, Controlled, Open-Label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 1 77Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptorpositive (SSTR+) , neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). COMPETE. ITM - LET - 01.
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Yaël Balderer
 Back-up:Frau Antje Kramer


Status: aktiv seit 27.12.2017

 
zurück nach oben

Oesophagus

  • zur Zeit keine aktive Studie
zurück nach oben

Ovar, Cervix

Ordner-Nr. 2017-00228

  • ICON8: An international phase 3 randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer
 Studienleiter:Fr. Dr. med. Manuela Rabaglio
 Study-Nurse:Frau Farzaneh Borner
 Back-up:Frau Olivia Aerni


Status: aktiv seit 24.07.2018

 
zurück nach oben

Pankreas

  • zur Zeit keine aktive Studie
zurück nach oben

Prostata

Ordner-Nr. 101/09

  • STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. A 5-stage 6-arm randomized controlled trial

    Externer Link
 Studienleiter:PD Dr. George Thalmann
Hinweis: Randomizations to arm G is stopped. Arms A and H (newly-diagnosed M1 patients)are still open. Meldung vom 17. Jan. 2014


Status: aktiv seit 10.10.2013

 

Ordner-Nr. 306/2014

  • SAKK 63/12: Prospective cohort study with collection of clinical data and serum of patients with prostate disease
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Fr. Sandra Fuchser
 Back-up:Frau Ulla Schüpbach


Status: aktiv seit 17.02.2015

 

Ordner-Nr. 2017-00842

  • EORTC Radiation Oncology Group EORTC Genito-Urinary Cancers Group (EORTC 1414-RO: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus)
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Frau Ulla Schüpbach


Status: aktiv seit 29.01.2018

 

Ordner-Nr. 2017-00584

  • SAKK 08/15 PROMET: Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy
 Studienleiter:Prof. Dr. Daniel Aebersold
 Study-Nurse:Frau Ulla Schüpbach


Status: aktiv seit 06.10.2017

 
zurück nach oben

Sarkome

Ordner-Nr. 2017-01449

  • EORTC ANITA: A Phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based first line chemotherapy for inoperable disease "ANITA"
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Nicole Corballis
 Back-up:Frau Antje Kramer


Status: aktiv seit 02.10.2018

 

Ordner-Nr. 2017-01063

  • E-trab: GERIATRIC ASSESSMENT OF ELDERLY “UNSUITED” PATIENTS RECEIVING TRABECTEDIN IN FIRST LINE TREATMENT FOR ADVANCED SOFT TISSUE SARCOMAS (STS)
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Antje Kramer


Status: aktiv seit 25.10.2017

 

Ordner-Nr. 3787

  • SAKK 57/16 : NAPAGE: NAb-PAclitaxel and GEmcitabine in advanced soft tissue sarcoma. A multicenter open-label single arm phase Ib/IIa trial
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Nicole Corballis


Status: aktiv seit 01.11.2018

 

Ordner-Nr. 2018-00788

  • EuroEwing 2012: Newly Diagnosed Ewing's Sarkoma Family of Tumours
 Studienleiter:Dr. med. Attila Kollar
 Study-Nurse:Frau Nicole Corballis
 Back-up:Frau Antje Kramer


Status: aktiv seit 02.10.2018

 
zurück nach oben

Solide Tumoren

  • zur Zeit keine aktive Studie
zurück nach oben

Supportivtherapie

  • zur Zeit keine aktive Studie
zurück nach oben

Urothelkarzinom/Nierenzellkarzinom

Ordner-Nr. 2017DR3115

  • E7080-G000-307: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Antje Kramer
 Back-up:Frau Silvia Andrist


Status: aktiv seit 10.10.2018

 

Ordner-Nr. 2017-01595

  • SAKK 07/17: Nivolumab in combination with Ipilimumab in patients with metastatic renal cell carcinoma: A multicenter single-arm phase lI trial
 Studienleiter:Dr. med. Julian Schardt
 Study-Nurse:Frau Antje Kramer
 Back-up:Frau Silvia Andrist
Hinweis: You have up to now enrolled 32 out of 35 to 37 patients into the SAKK 07/17 trial, thank you very much! This is to inform you that the trial approaches its accrual target and therefore we expect the closure of the trial within the next 4-8 weeks. To ensure that all informed patients can still be included before the target accrual is reached a reservation system is put into place starting as of today. Meldung der SAKK vom 31.10.2018


Status: aktiv seit 13.03.2018

 

Ordner-Nr. 2018-00176

  • SAKK 06/ 17 : Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II trial
 Co-Investigator:Dr. med. Julian Schardt
 Study-Nurse:Frau Silvia Andrist


Status: aktiv seit 00.00.0000

 

Ordner-Nr. 2018-00176

  • SAKK 06/17 : Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II trial
 Studienleiter:PD Dr.med. Roland Seiler
 Co-Investigator:Dr. med. Julian Schardt
 Study-Nurse:Frau Silvia Andrist
Hinweis: Studie wird in Zusammenarbeit mit der Urologie durchgeführt.


Status: aktiv seit 13.08.2018

 
zurück nach oben